June 07, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Berobenatide shows promise for monthly GLP-1 dosing
NEW ORLEANS — New data from three phase 2b studies demonstrate substantial weight loss with berobenatide, an ultralong-acting GLP-1 receptor agonist, in people with obesity or overweight, with and without type 2 diabetes.Both weekly and monthly dosing was feasible and well tolerated, researchers reported during a symposium at the American Diabetes Association Scientific Sessions.
1,464 words~7 min read
